🇺🇸 FDA
Patent

US 9796756

Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

granted A61PA61P1/16A61P3/00

Quick answer

US patent 9796756 (Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA) held by Arrowhead Pharmaceuticals, Inc. expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P1/16, A61P3/00, A61P31/12